ClinicalTrials.gg
RecruitingNCT05889013PCDUpdated Oct 5, 2026

Utility of PCD Diagnostics to Improve Clinical Care

An observational study in Primary Ciliary Dyskinesia, sponsored by Connecticut Children's Medical Center. Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Connecticut Children's Medical Center · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
50
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.

Planned enrollment
14th of 19
50 · median 150
Started
2023
with 4 others
Observational
19 of 28
4 open now
Registered
23rd of 28
by date
Lead sponsor
1 of 28
Connecticut Children's Medical Center

Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is the 14th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2023, is one of 19 observational ones, and was the 23rd registered.

Ciliary Motility Disorders

80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.

Browse Ciliary Motility Disorders studies →

Open to participants now

9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Ciliary Motility Disorders studies recruiting now, 15 (71%) set no upper age limit and 3 (14%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ciliary Motility Disorders with a site in United States, or all of them as a file.
02

Study summary

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

Read the detailed description

This is an observational study to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD. Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant. These providers will then refer for enrollment in the study based on the clinical considerations for a diagnosis of PCD. Participants will be consented during the time of testing at the Pulmonary department. Any patient referred by a clinician for concerns for PCD, including those who have had PCD genetics sent, or a ciliary biopsy performed will be enrolled in the study. In addition, any participant who is referred for nasal nitric oxide testing and meets the inclusion and exclusion criteria for this testing, will also need to provide informed consent and be enrolled in the Nasal NO REDCap registry. This equipment is not currently FDA approved or CLIA certified for PCD diagnostic testing and therefore referring clinicians will be informed that the results of this test should not influence clinical decision making regarding the diagnosis of PCD. However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed.

03

Conditions studied

  • Primary Ciliary Dyskinesia

Keywords

  • PCD
  • nasal nitric oxide testing
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population are ages 2 and up. Participant selection will be on a referral basis for the consideration of a clinical suspicion for PCD. Participants will be identified by pulmonary providers that consider testing for PCD based on the clinical symptoms of the participant. These providers will thenrefer for enrollment in the study based on the clinical considerations for a diagnosis of PCD.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 2 years of age
  • Must have two of the following clinical history points:
  • Neonatal respiratory distress
  • Chronic nasal congestion/runny nose
  • Chronic cough
  • Situs/laterality defects
  • Bronchiectasis
  • Ability to provide or consent of parent/guardian and ass

Exclusion criteria

Exclusion Criteria:

  • Recent history of sinus surgery or bloody nose in the past week
  • Age \< 2 years of age
  • Inability to tolerate probe in nose
  • Sinusitis or other respiratory exacerbation currently being treated with antibiotics
  • Admitted to hospital for respiratory exacerbation (inpatient status)
  • Inability to understand the requirements of the study or be unwilling to provide written (as evidenced by signature on an informed consent document approved by the IRB)
  • Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Nasal Nitric Oxide

    Participants who are referred by his/her clinician for nasal NO testing and meet the inclusion and exclusion criteria will undergo testing. Clinical information regarding prior diagnostic testing will be collected at time of enrollment. Participants that have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry

    Device: Nasal Nitric Oxide testing

Interventions

  • DeviceNasal Nitric Oxide testing

    Collection of already performed clinical data and nNO testing

    Also known as: nNO testing

06

What researchers measure

Primary outcomes

  1. Creation of Nasal NO REDCap registry

    To establish a research registry to characterize the features of individuals that undergo PCD diagnostic testing at Connecticut Children's Medical Center and UCONN.

    Time frame: 2-3 years

  2. Evaluation of utility of PCD diagnostic testing

    To evaluate the utility of PCD diagnostic testing, including potential use of nasal nitric oxide in comparison to genetic testing and ciliary biopsy, in pulmonary practice at Connecticut Children's Medical Center and UCONN.

    Time frame: 2-3 years

Secondary outcomes

  1. Refinement and Improvement of PCD Diagnostic Testing

    To refine and improve current diagnostic processes for PCD diagnosis at CCMC using information gathered from the research registry established through Primary aims 1 and 2.

    Time frame: 1-2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 5, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05889013
Lead sponsor
Connecticut Children's Medical Center
Collaborators
UConn Health
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Oct 17, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Melanie S Collins, MD
Contact
mcollin@connecticutchildrens.org
860-545-9440
Sigrid M Almeida, BS
Contact
salmeida@connecticutchildrens.org
8608375343
Melanie S Collins, MD
principal investigator · Connecticut Children's Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion